That's the risk of selling early.
Warner Lambert was lucky-It had marketing partnership with PFIZER who did great market research (inspite of bad Market research by Merck) and using it--advertised Lipitor.
Fortunately as Sales grew for Lipitor--WL stock started moving up from 45$ in 1996 to 150$ by end of 1997.
So if Pfizer was a marketing partner-I would be happier.
Reduce-IT results--will be known at the end of 2014 or middle of 2014--like Jupiter.
The difference is WL was in no hurry to sell itself.
For Amarin, Abingworth's Joseph Anderson will be the deciding factor.
As I remember Lipitor was a hard sell initially as there were already statin drugs on the market
Vascepa should find it easer due to unmet medical need Ie to lower TG without raising LDL